Cao Yu

Special PI Program with PKUSZjoshuacao(at)pku.edu.cn

Educational background&Work experience

2017-PresentPrincipal Investigator, Peking University, Shenzhen Graduate School

2016-2017Senior Scientist, Sorrento Therapeutics Inc. (USA)

2013-2016Research Associate, The Scripps Research Institute (Supervisor: Peter G. Schultz)

2007-2013 Postdoctoral Fellow, University of Texas, MD Anderson Cancer Center (Supervisor: Michael G. Rosenblum)

2001-2007Ph.D., Nankai University (Advisor: Gang Bai)

1996-2000 B.Sc., Liaoning University

Research field

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments to improve the clinical efficacy. By critical thinking the distinct cell killing efficacy and potential unwanted toxicity of different targeted strategies, Dr. Cao’s lab is building versatile platforms and finding optimal strategies to develop novel immunotherapeutic agents for cancer treatment. Dr. Cao’s goal is to design the precision medicine approach for individual cancer patient groups for fully realizing the potential benefits of immunotherapy.